Improved Screening Test for Idiopathic Infantile Hypercalcemia Confirms Residual Levels of Serum 24,25-(OH)2D3 in Affected Patients

Martin Kaufmann, Nicole Morse, Billy Joe Molloy, Donald P. Cooper, Karl Peter Schlingmann, Arnaud Molin, Marie Laure Kottler, J. Christopher Gallagher, Laura Armas, Glenville Jones

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

CYP24A1 mutations are now accepted as a cause of idiopathic infantile hypercalcemia (IIH). A rapid liquid-chromatography tandem mass spectrometry (LC-MS/MS)-based blood test enabling measurement of the 25-OH-D3:24,25-(OH)2D3 ratio (R) can identify IIH patients on the basis of reduced C24-hydroxylation of 25-OH-D3 by CYP24A1 in vivo. Although values of this ratio are significantly elevated in IIH, somewhat surprisingly, serum 24,25-(OH)2D3 remains detectable. The current study explores possible explanations for this including: residual CYP24A1 enzyme activity in individuals with certain CYP24A1 genotypes, expression of alternative C24-hydroxylases, and the possibility of isobaric contamination of the 24,25-(OH)2D3 peak on LC-MS/MS. We employed an extended 20-min run time on LC-MS/MS to study serum vitamin D metabolites in patients with IIH due to mutations of CYP24A1 or SLC34A1; in unaffected heterozygotes and dialysis patients; in patients with vitamin D deficiency; as well as in normal subjects exhibiting a broad range of 25-OH-D levels. We identified 25,26-(OH)2D3 as a contaminant of the 24,25-(OH)2D3 peak. In normals, the concentration of 24,25-(OH)2D3 greatly exceeds 25,26-(OH)2D3; however, 25,26-(OH)2D3 becomes more significant in IIH with CYP24A1 mutations and in dialysis patients, where 24,25-(OH)2D3 levels are low when CYP24A1 function is compromised. Mean R in 30 IIH-CYP24A1 patients was 700 (range, 166 to 2168; cutoff = 140) as compared with 31 in 163 controls. Furthermore, patients possessing CYP24A1 L409S alleles exhibited higher 24,25-(OH)2D3 levels and lower R (mean R = 268; n = 8) than patients with other mutations. We conclude that a chromatographic approach which resolves 24,25-(OH)2D3 from 25,26-(OH)2D3 produces a more accurate R that can be used to differentiate pathological states where CYP24A1 activity is altered. The origin of the residual serum 24,25-(OH)2D3 in IIH patients appears to be multifactorial.

Original languageEnglish (US)
Pages (from-to)1589-1596
Number of pages8
JournalJournal of Bone and Mineral Research
Volume32
Issue number7
DOIs
StatePublished - Jul 2017

Keywords

  • 24,25-(OH)D
  • 25,26-(OH)D
  • CYP24A1
  • HYPERCALCEMIA
  • LC-MS/MS

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Fingerprint Dive into the research topics of 'Improved Screening Test for Idiopathic Infantile Hypercalcemia Confirms Residual Levels of Serum 24,25-(OH)<sub>2</sub>D<sub>3</sub> in Affected Patients'. Together they form a unique fingerprint.

  • Cite this

    Kaufmann, M., Morse, N., Molloy, B. J., Cooper, D. P., Schlingmann, K. P., Molin, A., Kottler, M. L., Gallagher, J. C., Armas, L., & Jones, G. (2017). Improved Screening Test for Idiopathic Infantile Hypercalcemia Confirms Residual Levels of Serum 24,25-(OH)2D3 in Affected Patients. Journal of Bone and Mineral Research, 32(7), 1589-1596. https://doi.org/10.1002/jbmr.3135